Kühböck J
II. Medical Department, University of Vienna, Austria.
Semin Surg Oncol. 1988;4(2):87-90.
A critical survey is made of cytotoxic chemotherapy of metastatic renal cancer. On the basis of representative summaries, only a few substances such as vinblastine, CCNU, hydroxyurea, and ifosfamide seem to act with some degree of success, but no specific antirenal cancer agent has as yet become available. This outline should provide a more realistic view of the therapeutic possibilities and of the limits of cytostatic chemotherapy in the metastatic phase of renal cancer. It is postulated that chemotherapy should feature more prominently in future therapeutic strategies. Newer cytostatic substances, i.e., second-generation alkylating agents and anthracyclines as well as platinum analogues, may present an advance with regard to side effects and tolerance but are discouraging with regard to their therapeutic efficiency in metastatic renal cancer.
对转移性肾癌的细胞毒性化疗进行了批判性综述。根据代表性总结，只有少数几种物质，如长春碱、洛莫司汀、羟基脲和异环磷酰胺，似乎有一定程度的疗效，但尚未有特异性的抗肾癌药物问世。本概述应能更现实地看待细胞抑制化疗在肾癌转移阶段的治疗可能性及局限性。据推测，化疗在未来的治疗策略中应发挥更突出的作用。新型细胞抑制物质，即第二代烷化剂、蒽环类药物以及铂类类似物，在副作用和耐受性方面可能有所进展，但在转移性肾癌的治疗效果方面却令人沮丧。
